WLWT: Avondale man encourages community to consider impact of heart health
UC cardiologist sounds warning about heart disease as part of American Heart Month
Heart disease is the No. 1 killer of women and men. The American Heart Association says cardiovascular disease claims the lives of 1 in 3 women about every 80 seconds. Dr. Hina Jamali, assistant professor in the UC College of Medicine and UC Health cardiologist, told a journalist with WLWT-Channel 5 that medical professionals have to be intentional in educating the community about heart health symptoms.
The most common symptom is chest pain or tightness, but for women, it may not be the most severe, said Jamali. Women are more likely to experience other symptoms like indigestion, back or jaw pain, fatigue or shortness of breath.
Jamali offered her insight as part of American Heart Month; February is designated as such to call attention to heart disease in the United States.
"About 650,000 Americans get affected and are killed by heart disease per year," Jamali said. "We see more men in their younger years -- like 35 plus, 40s -- than women in their age group. Women, I would say it hits them five to 10 years later."
Listen to Dr. Jamali's interview with WLWT-Channel 5
Hear Dr. Jamali speak about National Wear Red Day with WLWT-Channel 5
Related Stories
UC Board of Trustees approves $12 million for building design phase for new welcome gateway
March 13, 2026
The UC Board of Trustees approved $12 million at its Feb. 24 meeting for the design phase of a new Welcome Gateway Building for Uptown campus.
Breakthrough skin science discovery
March 12, 2026
A research collaboration between the University of Cincinnati and global cosmetics company Kose led to the creation of a novel anti aging spot fading serum.
Study: Additional radiation for liver cancer does not increase toxicity
March 10, 2026
New research led by University of Cincinnati Cancer Center researchers published in the American Journal of Clinical Oncology found external beam radiation therapy (EBRT) is safe to administer to patients with liver cancer even after they undergo a targeted internal radiation therapy called Y90.